{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:17Z","timestamp":1793933717189,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u201c1+X\u201d program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University","award":["2022LCYJZD02"],"award-info":[{"award-number":["2022LCYJZD02"]}]},{"name":"Dalian Medical Science Research Program Projec","award":["2312015"],"award-info":[{"award-number":["2312015"]}]},{"name":"Dalian Municipal Guidance Plan Initiative for the Life and Health Sector","award":["2024ZDJH01PT113"],"award-info":[{"award-number":["2024ZDJH01PT113"]}]},{"name":"\u201c1+X\u201dResearch Project of the Second Hospital of Dalian Medical University","award":["CYQH2024016"],"award-info":[{"award-number":["CYQH2024016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to evaluate the prognostic significance of lactate dehydrogenase (LDH) and fasting triglyceride-glucose (TyG) index in advanced hormone-sensitive prostate cancer (HSPC) patients, with the ultimate goal of developing and validating a nomogram for predicting castration-resistant prostate cancer (CRPC) free survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>The follow-up data of 207 CRPC patients who had androgen deprivation therapy as their initial and only treatment before progression were retrospectively reviewed. To assess prognostic variables, univariate and multivariate Cox regression analyses were performed. The concordance index (C-index), calibration curves, receiver operating characteristic (ROC) curves, and decision curve analyses (DCA) were utilized to construct and test a novel nomogram model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>TyG index, LDH, M stage and Gleason sum were determined to be independent prognostic markers and were combined to create a nomogram. This nomogram worked well in the tailored prediction of CRPC development at the sixth, twelve, eighteen, and twenty-fourth months. The C-indexes for the training and validation sets were 0.798 and 0.790, respectively. The ROC curves, calibration plots, and DCA all indicated good discrimination and prediction performance. Furthermore, the nomogram had a higher prognostic ability than the M stage and the Gleason sum. The nomogram-related risk score classified the patient population into two groups with significant progression differences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The created nomogram could help identify patients at high risk for rapid progression of advanced HSPC, allowing for the formulation of tailored therapy regimens and follow-up methods in a timely manner.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14035-w","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:40:02Z","timestamp":1744116002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Construction and validation of a nomogram for identifying the patients at risk for rapid progression of advanced hormone-sensitive prostate cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaolong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"14035_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M. Sung H, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 1\u201335.","DOI":"10.3322\/caac.21834"},{"issue":"1","key":"14035_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"14035_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41391-022-00618-2","volume":"26","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yan X, Tang P, et al. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023;26:180\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"14035_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract. 2011;65:1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"14035_CR5","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest oncology group trials 9346 (Intergroup study 0162) and 9916. J Clin Oncol. 2009;27:2450\u20136.","journal-title":"J Clin Oncol"},{"key":"14035_CR6","doi-asserted-by":"publisher","first-page":"102441","DOI":"10.1016\/j.ctrv.2022.102441","volume":"110","author":"G Fallara","year":"2022","unstructured":"Fallara G, Robesti D, Nocera L, Raggi D, Marandino L, Belladelli F, Montorsi F, Malavaud B, Ploussard G, Necchi A, Martini A. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. Cancer Treat Rev. 2022;110:102441.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"14035_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.prnil.2022.01.001","volume":"10","author":"S Chikamatsu","year":"2022","unstructured":"Chikamatsu S, Shiota M, Yamada S, Blas L, Matsumoto T, Kashiwagi E, Inokuchi J, Shiga KI, Yokomizo A, Eto M. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. Prostate Int. 2022;10(1):7\u201313.","journal-title":"Prostate Int"},{"key":"14035_CR8","doi-asserted-by":"crossref","unstructured":"Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord (2020) 20.","DOI":"10.1186\/s12902-020-00581-w"},{"key":"14035_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.clnesp.2022.08.004","volume":"51","author":"H Shi","year":"2022","unstructured":"Shi H, Zhou L, Yang S, Zhou H. The relationship between triglyceride and glycose (TyG) index and the risk of gynaecologic and breast cancers. Clin Nutr ESPEN. 2022;51:345\u201352.","journal-title":"Clin Nutr ESPEN"},{"key":"14035_CR10","doi-asserted-by":"crossref","unstructured":"Liu Y, Yuan L, Lin Z et al. The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. Clin Transl Oncol (2024).","DOI":"10.1007\/s12094-024-03569-3"},{"issue":"6","key":"14035_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/JU.0000000000002931","volume":"208","author":"A Bobrowski","year":"2022","unstructured":"Bobrowski A, Anson-Cartwright L, Kuhathaas K, Jiang DM, Chung P, Bedard P, et al. Role of lactate dehydrogenase in identifying relapse for patients with stage I testicular cancer on surveillance. J Urol [Internet]. 2022;208(6):1250\u20138. Dec 1 [cited 2024 Jul 23];.","journal-title":"J Urol [Internet]"},{"key":"14035_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/CMAR.S403445","volume":"15","author":"I Karadag","year":"2023","unstructured":"Karadag I, Karakaya S, Akkan T, Demir B, Alkurt EG, Dogan M. The potential prognostic marker TyG index predicts time to brain metastasis at HER2 positive breast cancer. Cancer Manage Res. 2023;15:311\u20137.","journal-title":"Cancer Manage Res"},{"key":"14035_CR13","doi-asserted-by":"publisher","first-page":"1098492","DOI":"10.3389\/fendo.2022.1098492","volume":"13","author":"H Wang","year":"2023","unstructured":"Wang H, Yan FF, Cui YN, Chen FN, Wang GX, Cui WW. Association between triglyceride glucose index and risk of cancer: A meta-analysis. Front Endocrinol. 2023;13:1098492.","journal-title":"Front Endocrinol"},{"issue":"2","key":"14035_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3892\/ijo.2017.3844","volume":"50","author":"CC Lu","year":"2017","unstructured":"Lu CC, Chu PY, Hsia SM, Wu CH, Tung YT, Yen GC. Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells. Int J Oncol. 2017;50(2):736\u201344.","journal-title":"Int J Oncol"},{"key":"14035_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/jhn.13051","volume":"36","author":"N Joharatnam-Hogan","year":"2023","unstructured":"Joharatnam-Hogan N, Morganstein DL. Diabetes and cancer: optimising glycaemic control. J Hum Nutr Diet. 2023;36:504\u201313.","journal-title":"J Hum Nutr Diet"},{"issue":"10","key":"14035_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1158\/1055-9965.EPI-17-0293","volume":"26","author":"SJ Ilona Argirion","year":"2017","unstructured":"Ilona Argirion SJ, Weinstein S, M\u00e4nnist\u00f6 D, Albanes AM. Mondul; serum insulin, glucose, indices of insulin resistance, and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 1 Oct. 2017;26(10):1519\u201324.","journal-title":"Cancer Epidemiol Biomarkers Prev 1 Oct"},{"issue":"4","key":"14035_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/0284186X.2023.2197124","volume":"62","author":"JM M\u00e0rmol","year":"2023","unstructured":"M\u00e0rmol JM, Carlsson M, Raun SH, Grand MK, S\u00f8rensen J, Lehrskov L, Sylow L, L. Insulin resistance in patients with cancer: a systematic review and meta-analysis. Acta Oncol. 2023;62(4):364\u201371.","journal-title":"Acta Oncol"},{"key":"14035_CR18","doi-asserted-by":"publisher","first-page":"106775","DOI":"10.1016\/j.phrs.2023.106775","volume":"194","author":"R Reyadh","year":"2023","unstructured":"Reyadh R, Al-Rashidi S, Abdalrazzaq M, Noraldeen AK, Kareem, et al. Malignant function of nuclear factor-kappaB axis in prostate cancer: molecular interactions and regulation by non-coding RNAs. Pharmacol Res. 2023;194:106775.","journal-title":"Pharmacol Res"},{"issue":"18","key":"14035_CR19","first-page":"3950","volume":"41","author":"J Chen","year":"2021","unstructured":"Chen J, An H, Li L. Blood lipid levels and clinical significance in patients with prostate cancer. Chin J Gerontol. 2021;41(18):3950\u20132.","journal-title":"Chin J Gerontol"},{"key":"14035_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.12229","volume":"16","author":"S O\u2019Neill","year":"2015","unstructured":"O\u2019Neill S, O\u2019Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1\u201312.","journal-title":"Obes Rev"},{"key":"14035_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-021-00471-8","volume":"17","author":"P Morigny","year":"2021","unstructured":"Morigny P, Boucher J, Arner P, et al. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nat Rev Endocrinol. 2021;17:276\u201395.","journal-title":"Nat Rev Endocrinol"},{"key":"14035_CR22","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1096\/fj.201700159R","volume":"31","author":"T Meng Guanmin","year":"2017","unstructured":"Meng Guanmin T, Xiaoyun Y, Zelei, et al. Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy. FASEB J. 2017;31:4064\u201377.","journal-title":"FASEB J"},{"key":"14035_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CCO.0000000000000519","volume":"31","author":"A Kaiser","year":"2019","unstructured":"Kaiser A, Haskins C, Siddiqui MM, Hussain A, D\u2019Adamo C. The evolving role of diet in prostate cancer risk and progression. Curr Opin Oncol. 2019;31:222\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"3573","key":"14035_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1126\/science.140.3573.1329","volume":"140","author":"CL Markert","year":"1963","unstructured":"Markert CL. Lactate dehydrogenase isozymes: dissociation and recombination of subunits. Science. 1963;140(3573):1329\u201330.","journal-title":"Science"},{"key":"14035_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","volume":"19","author":"G Claps","year":"2022","unstructured":"Claps G, Faouzi S, Quidville V, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19:749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"14035_CR26","doi-asserted-by":"publisher","first-page":"23111","DOI":"10.1074\/jbc.M202487200","volume":"277","author":"H Lu","year":"2002","unstructured":"Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic Glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111\u20135.","journal-title":"J Biol Chem"},{"issue":"1","key":"14035_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"14035_CR28","doi-asserted-by":"crossref","unstructured":"Junchen Liu G, Chen Z, Liu, et al. Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer. Cancer Res. August 2018;15(16):4459\u201370.","DOI":"10.1158\/0008-5472.CAN-17-3226"},{"key":"14035_CR29","doi-asserted-by":"publisher","first-page":"1280221","DOI":"10.3389\/fendo.2023.1280221","volume":"14","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li T, Muheiyati G, Duan Y, Xiao S, Gao Y, Tao N, An H. Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population. Front Endocrinol. 2024;14:1280221.","journal-title":"Front Endocrinol"},{"key":"14035_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41416-023-02526-1","volume":"130","author":"J Fritz","year":"2024","unstructured":"Fritz J, Jochems SHJ, Bj\u00f8rge T, et al. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Br J Cancer. 2024;130:308\u201316.","journal-title":"Br J Cancer"},{"key":"14035_CR31","doi-asserted-by":"publisher","first-page":"e16158","DOI":"10.7717\/peerj.16158","volume":"11","author":"R Qiu","year":"2023","unstructured":"Qiu R, Bu K, An H, Tao N. A retrospective study: analysis of the relationship between lactate dehydrogenase and castration-resistant prostate cancer based on restricted cubic spline model. PeerJ. 2023;11:e16158.","journal-title":"PeerJ"},{"issue":"18","key":"14035_CR32","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3390\/cancers16183198","volume":"16","author":"H Iwamoto","year":"2024","unstructured":"Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Mizokami A. Novel treatment strategies for Low-Risk metastatic Castration-Sensitive prostate cancer. Cancers (Basel). 2024;16(18):3198.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14035-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:19:57Z","timestamp":1744219197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14035-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14035"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14035-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was accepted by the ethical committee of the Second Hospital of Dalian Medical University (number: 2023064) with the Declaration of Helsinki. All patients consented to the medical treatment, specifically to have their medical records used in research, and submitted written informed consent prior to data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"634"}}